# Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct04133168` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04133168](<https://clinicaltrials.gov/study/NCT04133168>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04133168

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.

## Technical summary

Registry record NCT04133168. Allocation not applicable; no masking; primary purpose treatment. Start 2020-06-24 (actual); primary completion 2022-11-10 (actual). Results posted on 2023-12-07.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 458 participants (enrolled count; ClinicalTrials.gov record NCT04133168, source copy `cardio:ctgov-nct04133168-2025-04-03`, retrieved 2026-10-26)
- Started: 2020-06-24 (actual) (ClinicalTrials.gov record NCT04133168, source copy `cardio:ctgov-nct04133168-2025-04-03`, retrieved 2026-10-26)
- Primary completion: 2022-11-10 (actual) (ClinicalTrials.gov record NCT04133168, source copy `cardio:ctgov-nct04133168-2025-04-03`, retrieved 2026-10-26)
- Completion: 2023-08-17 (actual) (ClinicalTrials.gov record NCT04133168, source copy `cardio:ctgov-nct04133168-2025-04-03`, retrieved 2026-10-26)
- Results first posted: 2023-12-07 (ClinicalTrials.gov record NCT04133168, source copy `cardio:ctgov-nct04133168-2025-04-03`, retrieved 2026-10-26)
- Countries: United States; Belgium; Canada; France; Germany; Hong Kong SAR China; Italy; Netherlands; Taiwan (ClinicalTrials.gov record NCT04133168, source copy `cardio:ctgov-nct04133168-2025-04-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04133168-2025-04-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation
- Acronym: FROZEN-AF
- Condition: Paroxysmal Atrial Fibrillation
- Intervention (Device): Boston Scientific Cardiac Cryoablation System
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: b91ebc9290b8343d2e1ca01a543410a156a6831564f058db4740b6436bdd05b8
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
